What is Candel Therapeutics Inc Annual Net Profit?

Candel Therapeutics Inc Annual Net Profit fell 45.44% in the last year to $55.18 M. Its sector's average net profit growth for the last fiscal year was -17.3%.

What is Candel Therapeutics Inc Price to Earning Ratio?

Candel Therapeutics Inc Price to Earning Ratio is -4.06, which is negative.

What is Candel Therapeutics Inc Stock Price?

Candel Therapeutics Inc Stock Price fell 8.32% and underperformed its sector by 21.85% in the past year.

What is Candel Therapeutics Inc Quarterly Net profit?

Candel Therapeutics Inc Quarterly Net profit fell 26.84% YoY to $14.07 M. Its sector's average net profit growth YoY for the quarter was -51.5%.

What is Candel Therapeutics Inc Debt to Equity Ratio?

Candel Therapeutics Inc Debt to Equity Ratio of 0.2 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Candel Therapeutics Inc Return on Equity(ROE)?

Candel Therapeutics Inc Return on Equity(ROE) for the last financial year was -139.56%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Candel Therapeutics Inc Mutual Fund Holding?

Candel Therapeutics Inc Mutual Fund Holding increased by 5.67% in the last quarter to 26.04.

What is Candel Therapeutics Inc Interest Coverage Ratio?

Candel Therapeutics Inc Interest Coverage Ratio is -25.4, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Candel Therapeutics Inc Institutional Holding?

Candel Therapeutics Inc Institutional Holding increased by 0.02% in the last quarter to 38.22.

How is the Candel Therapeutics Inc today?

The Candel Therapeutics Inc today is trading in the green, up by 5.10% at 4.74.

How has Candel Therapeutics Inc performed historically?

The Candel Therapeutics Inc is currently trading up 5.10% on an intraday basis in the past week the index fell -8.32%. The index has been down -28.18% in the past quarter and fell -8.32% in the past year. You can view this in the overview section.

Candel Therapeutics Inc XNAS: CADL

Candel Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Candel Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Candel Therapeutics Inc
Rating: 1.18400
Author: Trendlyne DVM scores

Download real time

4.74 0.23 (5.10%)

67.53% Fall from 52W High

526.0K XNAS Volume

XNAS 22 Apr, 2025 5:30 PM (EDT)

Candel Therapeutics Inc Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	223.9
PE TTM Negative PE TTM Unavailable in chosen country	-4.1
PEG TTM Below industry Median Unavailable in chosen country	0.1
Price to Book Below industry Median Unavailable in chosen country	3.4
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	38.2
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-26.8
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-45.4
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-24.8
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-139.6
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-74.5

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

5.0 / 100

Technically Neutral

42.4 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Candel Therapeutics Inc Stock Price Analysis

Day Price Range 5.1% 1 Day return Unavailable in chosen country	4.7 (LTP) 4.64.8 LowHigh
Week Price Range -8.3% 1 Week return Unavailable in chosen country	4.7 (LTP) 4.45.3 LowHigh
Month Price Range -41.2% 1 Month return Unavailable in chosen country	4.7 (LTP) 4.28.7 LowHigh
52 Week Price Range -8.3% 1 Year return Unavailable in chosen country	4.7 (LTP) 3.814.6 LowHigh

View full Share Price History

Candel Therapeutics Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Candel Therapeutics Inc's Revenue was higher than average estimate 1 time in past 1 year

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Candel Therapeutics Inc Stock Analysis

Candel Therapeutics Inc stock analysis with key metrics, changes, and trends.

Candel Therapeutics Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$55.18 M	45.44%	negative	Annual Net Profit fell 45.44% in the last year to $55.18 M. Its sector's average net profit growth for the last fiscal year was -17.3%.
Price to Earning Ratio	-4.06	-	negative	Price to Earning Ratio is -4.06, which is negative.
Stock Price	$4.74	-8.32%	negative	Stock Price fell 8.32% and underperformed its sector by 21.85% in the past year.
Quarterly Net profit	$14.07 M	26.84%	negative	Quarterly Net profit fell 26.84% YoY to $14.07 M. Its sector's average net profit growth YoY for the quarter was -51.5%.
Debt to Equity Ratio	0.2	-	positive	Debt to Equity Ratio of 0.2 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-139.56 %	-139.56%	negative	Return on Equity(ROE) for the last financial year was -139.56%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	26.04 %	5.67%	positive	Mutual Fund Holding increased by 5.67% in the last quarter to 26.04.
Interest Coverage Ratio	-25.4	-	negative	Interest Coverage Ratio is -25.4, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	38.22 %	0.02%	positive	Institutional Holding increased by 0.02% in the last quarter to 38.22.

VIEW LESS

Loading data..

Candel Therapeutics Inc - Company Profile

What does Candel Therapeutics Inc do?

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Gross Remuneration

2024

Gross Remuneration

Year

Candel Therapeutics Inc Live Share Price Today, Share Analysis and Chart

67.53% Fall from 52W High

Candel Therapeutics Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Candel Therapeutics Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Candel Therapeutics Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Candel Therapeutics Inc's Revenue was higher than average estimate 1 time in past 1 year

Candel Therapeutics Inc Stock Analysis

Candel Therapeutics Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 45.44% in the last year to $55.18 M. Its sector's average net profit growth for the last fiscal year was -17.3%.

Price to Earning Ratio is -4.06, which is negative.

Stock Price fell 8.32% and underperformed its sector by 21.85% in the past year.

Quarterly Net profit fell 26.84% YoY to $14.07 M. Its sector's average net profit growth YoY for the quarter was -51.5%.

Debt to Equity Ratio of 0.2 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -139.56%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 5.67% in the last quarter to 26.04.

Interest Coverage Ratio is -25.4, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding increased by 0.02% in the last quarter to 38.22.

Candel Therapeutics Inc - Company Profile

What does Candel Therapeutics Inc do?

Candel Therapeutics Inc Management structure

Mr. Jason A. Amello

Chief Financial Officer, Treasurer, Secretary and Principal Accounting Officer

Mr. Charles Schoch

Interim Chief Financial Officer and Principal Accounting Officer

Dr. Paul Peter Tak, M.D.,PhD

President, Chief Executive Officer and Director

Candel Therapeutics Inc Board of directors

Mr. Joseph C. Papa

Independent Director

Mr. Paul B. Manning

Chairman of the Board

Dr. Edward J. Benz, Jr,M.D.

Independent Director

Ms. Renee M. Gaeta

Independent Director

Dr. Diem Nguyen, M.B.A.,PhD

Independent Director

Dr. Gary J. Nabel, M.D.,PhD

Independent Director

Candel Therapeutics Inc FAQ

How is Candel Therapeutics Inc today?

Candel Therapeutics Inc today is trading in the green, and is up by 5.10% at 4.74.

How has Candel Therapeutics Inc performed historically?

Candel Therapeutics Inc is currently trading up 5.10% on an intraday basis. In the past week the stock fell -8.32%. stock has been down -28.18% in the past quarter and fell -8.32% in the past year. You can view this in the overview section.